Zenagamtide
What it is & what research shows
Study example availableZenagamtide, formerly amycretin, is an investigational peptide combining GLP-1 and amylin activity in one molecule; the published papers also describe calcitonin receptor agonism. Oral daily and injectable weekly formulations have separate phase 2 reports in type 2 diabetes. Glucose control and weight change are different endpoints. The oral study summary below focuses on its primary HbA1c outcome. [1.1][1.2][1.3][1.4]
One selected study: A double-blind randomized phase 2 trial tested oral zenagamtide versus placebo for glucose control. 186 adults with type 2 diabetes taking metformin, with or without an SGLT2 inhibitor. Daily oral treatment titrated to 6, 25 or 50 mg; 36-week intervention. Estimated HbA1c reductions were 0.9, 1.3 and 1.4 percentage points; placebo-adjusted differences were 0.5, 0.99 and 1.09 points. Gastrointestinal events affected 26%, 41% and 47%, versus 23% with placebo. Seven active-treatment participants had serious adverse events; none were reported with placebo. On-treatment efficacy analysis without rescue medication. This oral study cannot inherit injectable weight-loss results. Serious events were reported, not necessarily attributed to treatment. [2.1]
Sources & reading scope
- [1.1] Oral zenagamtide: phase 2 trial in type 2 diabetesPublished human study · Daily oral formulation; HbA1c was the primary outcome.
- [1.2] Oral zenagamtide phase 2 trial recordTrial registration · Study design and any posted results; registration does not establish treatment benefit.
- [1.3] Injectable zenagamtide: phase 2 publicationPublished human study · Weekly injectable formulation; separate results from the oral study.
- [1.4] Zenagamtide: injectable phase 2 findingsSponsor report · Glucose and weight outcomes in 262 adults with type 2 diabetes.
- [2.1] Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial.Human · Abstract summarized · not a full-paper review
Evidence summarized on PED Evidence
3 completed summaries
3 human-study reports
3 randomized-trial candidates
3 safety-topic reports
Studies & trial records
Original papers, trial registrations and sponsor disclosures are labeled separately. Multiple links may describe the same study.
More about Zenagamtide: identity, safety & reference details
Also known as amycretin · NNC0487-0111
Start with the research
An outcome-specific synthesis has not been prepared for this compound. This is a coverage gap, not evidence that it has no effect.
Open studies and trial records- Uses & research
Oral daily and injectable weekly formulations have separate phase 2 reports in type 2 diabetes. Glucose control and weight change are different endpoints. The oral study summary below focuses on its primary HbA1c outcome. [1][2][3][4]
- Known half-life
No source-verified value in this profile yet. A treatment schedule or duration of an effect is not a drug half-life.
Half-life describes how quickly the measured drug concentration falls by half. It does not set a dosing interval.
Safety & evidence boundaries
Do not transfer injectable weight-loss percentages to the oral formulation. Gastrointestinal adverse events were common. Neither formulation is interchangeable with tirzepatide, and comparisons across separate trials cannot establish superiority.
Explore safety questions by system
These are literature filters, not claims that this compound causes each effect. A keyword match is not a confirmed adverse reaction.
Identity, names & formulations
Canonical compound: Zenagamtide · zenagamtide
Searchable names: amycretin, NNC0487-0111
Names share a parent research page. Different esters, salts, routes and brands are not assumed to have the same half-life, indication or exposure.
Combination evidence stays attached to the studied combination. It is not automatically assigned to each ingredient.
Understand the evidence types
Read the model and design first, then the population, outcome and limitations. These categories describe evidence, not a best-compound ranking.
- Randomized human trials
- Compare assigned interventions. Randomization does not by itself establish low bias or relevance to every population.
- Controlled human studies
- Use a comparison group; allocation and confounding still matter.
- Prospective human research
- Follows participants forward. It may be observational or interventional, so this is not a separate quality grade.
- Observational human research
- Describes associations. Confounding can explain differences.
- Case reports and series
- Useful for unusual events and safety signals, not reliable rates or effect sizes.
- Animal research
- Can test biology and function in a living model. Human exposure, benefit and safety remain separate questions.
- Cell and tissue research
- Tests responses in a preparation, including human-derived cells. It is not a human participant trial.
- Mechanistic and computational evidence
- Helps explain or predict a pathway; predictions need experimental and clinical testing.
- Anecdotal reports
- Self-reported experiences can generate questions. Product identity, selection bias and other interventions may be uncontrolled.
Systematic reviews synthesize studies and depend on their quality. Preprint status and abstract versus full-paper reading are separate labels. Citation popularity measures attention, not reliability. A study summary is not a formal quality appraisal.
Sources for this profile
- 1. Oral zenagamtide: phase 2 trial in type 2 diabetes Published human study · Daily oral formulation; HbA1c was the primary outcome.
- 2. Oral zenagamtide phase 2 trial record Trial registration · Study design and any posted results; registration does not establish treatment benefit.
- 3. Injectable zenagamtide: phase 2 publication Published human study · Weekly injectable formulation; separate results from the oral study.
- 4. Zenagamtide: injectable phase 2 findings Sponsor report · Glucose and weight outcomes in 262 adults with type 2 diabetes.
Reference facts checked 2026-09-24. Source scope is listed above; this is not a formal quality appraisal. See each label for full prescribing information.
Study model describes the source. Confidence depends on methods, replication, population and outcome.
Loading compound research…
Zenagamtide study summaries
Human-first reading order. Intervention candidates are distinguished from background mentions in the library.
- Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial. · Human · 2026-07-30
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial. · Human · 2025-06-20
- Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study. · Human · 2025-06-20